Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 2

1(20.0%)

Phase 3

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(2)

Phase 2(1)

Phase 3(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03558243Not ApplicableUnknown

Prevention of Radial Artery Occlusion: Comparison of Three HEmostatiC Methods in Transradial Intervention

Role: lead

NCT02083211Phase 3Completed

Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma

Role: collaborator

NCT01322308Phase 4Completed

Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus

Role: lead

NCT00552747Phase 4Completed

Effect of Fenofibrate on Endothelial Function and High-density Lipoproteins (HDL)in Patients With Coronary Heart Disease

Role: lead

NCT00725738Phase 2Unknown

Intracoronary Autologous Stem Cell Transplantation in ST Elevation Myocardial Infarction: TRACIA STUDY.

Role: lead

NCT00467311Completed

Cystatin C as an Early Marker of Contrast-Medium Nephropathy in Cardiac Catheterization Patients

Role: lead

All 6 trials loaded